News & Events

• May 17, 2018
  New Collaboration Seeks to Speed Huntington’s Disease Drug Licensing

  This article originally appeared on HDBuzz and is reprinted here under Creative Commons license. Critical Path Institute launches new initiative to get HD drugs licensed as quickly as possible By Dr Jeff Carroll, Edited by Dr Ed Wild Originally published here on May 09, 2018 Recently the Critical Path Institute announced a new effort – the Huntington’s Disease......
• March 14, 2018
  Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin

  Patel N, Hatley O, Berg A, Romero K, Wisniowska B, Hanna D, et al. Towards Bridging Translational Gap in Cardiotoxicity Prediction: an Application of Progressive Cardiac Risk Assessment Strategy in TdP Risk Assessment of Moxifloxacin. AAPS J. 2018 May 1;20(3):47.

• March 8, 2018
  Quantitative Approach for Cardiac Risk Assessment and Interpretation in Tuberculosis Drug Development

  Polak S, Romero K, Berg A, Patel N, Jamei M, Hermann D, et al. Quantitative approach for cardiac risk assessment and interpretation in tuberculosis drug development. J Pharmacokinet Pharmacodyn. 2018 Mar 8;1–11.

• February 27, 2018
  Patient-Reported Outcome (PRO) Consortium Translation Process: Consensus Development of Updated Best Practices

  Eremenco S, Pease S, Mann S, Berry P, on behalf of the PRO Consortium’s Process Subcommittee. Patient-Reported Outcome (PRO) Consortium translation process: consensus development of updated best practices. Journal of Patient-Reported Outcomes. 2017;(2):12.

• January 22, 2018
  Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort

  Church RJ, Kullak-Ublick GA, Aubrecht J, Bonkovsky HL, Chalasani N, Fontana RJ, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: An international collaborative effort. Hepatology. 2018 Jan 22.